Pharmaceutical Brand Names: Navigating the PTO/FDA Rapids
The program will explore how pharmaceutical brand names were historically and are currently examined by the trademark offices in the US and internationally and how their criteria differ in important ways from those of the FDA, EMA, and other regulatory authorities who must also approve pharmaceutical brand names. We will discuss strategies for managing these different approaches and present a mock case study with audience participation to more fully explore the optimal practices for securing regulatory approval and legal protection for pharmaceutical brand names.
Sponsored by the Committee on Continuing Legal Education, the Food, Drug and Cosmetic Law Section, and the Trademark Committee of the Intellectual Property Law Section of the New York State Bar Association.
Thank You to the Following Host Sponsor:
FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Tuesday, May 1, 2018
8:30 a.m. - 11:00 a.m.
Live CLE Program with Networking Breakfast
Fross Zelnick Lehrman & Zissu, P.C.
4 Times Square, 17th Floor
New York, NY 10036
2.0 MCLE Credits: 2.0 Areas of Professional Practice
NYSBA Member: $50 | Non-Member: $100
FDC Section Member: $25
IP Section Member: $25
· How US trademark law works and the impact of same on pharmaceutical brand name clearance.
· How EU and Canadian trademark law works and the impact of same on pharmaceutical brand name clearance in contrast to US law.
· Issues that branding agencies consider when developing and market testing pharmaceutical brand names and how to avoid potential problems.
David S. Weinstock, Esq.
Nadine H. Jacobson, Esq. | Partner | Fross, Zelnick, Lehrman & Zissu, P.C.Register
William T. Johnson | President | Brand Institute, Inc.
Laurence Rickles, Esq. | Chief Trademark Counsel | Teva Pharmaceuticals, Inc.